Composition and methods for detecting cancer
AssigneesCentre National De La Recherche Scientifique, Institut National De La Sante Et De La Rech. Med., Universite Paris Est Creteil Val De Marne
InventorsValérie Molinier Frenkel, Flavia Castellano
Life of this patent
Estimating the term…
Abstract
The invention relates to antibodies, which bind a peptide having a sequence selected from SEQ ID NO: 2, or a fragment or derivative of such an antibody having essentially the same antigen specificity. In particular, the antibodies suited to be used to detect, manage or monitor cancer in a subject, particularly cancer with interleukin-4 induced gene 1 (IL4I1) expressing cells. The invention also relates to kits or devices containing said antibodies, suitable for immunologic detection or reaction from any biological sample.
Claims8
An isolated monoclonal antibody comprising:
- a heavy chain comprising variable domain CDR sequences comprising:
- (a) a H-CDR1 comprising the sequence of SEQ ID NO:
- 8,
- (b) a H-CDR2 comprising the sequence of SEQ ID NO:
- 9 or SEQ ID NO:
- 18, and
- (c) a H-CDR3 comprising the sequence of SEQ ID NO:
- 10 or SEQ ID NO:
- 19;
- and
- a light chain comprising variable domain CDR sequences comprising:
- (a) a L-CDR1 comprising the sequence of SEQ ID NO:
- 5,
- (b) a L-CDR2 comprising the sequence of SEQ ID NO:
- 6 or SEQ ID NO:
- 14, and
- (c) a L-CDR3 comprising the sequence of SEQ ID NO:
- 7 or SEQ ID NO:
- 15.
An isolated monoclonal antibody produced from the hybridoma cell available under CNCM deposit number I-5355.
Dependencies are inferred from the claim text.